Publications by authors named "D Tramontano"
Article Synopsis
- Homozygous familial hypercholesterolemia (HoFH) is a genetic disorder that leads to very high LDL cholesterol levels and increased risk for heart disease, and lomitapide shows potential to lower LDL cholesterol levels.
- A study analyzed the effects of lomitapide on 38 women and 37 men with HoFH, finding similar LDL reduction rates for both sexes, although women showed a greater reduction at six months.
- Women experienced more gastrointestinal side effects from the treatment, but overall, lomitapide was similarly effective for both genders in reducing cholesterol without significant differences in cardiovascular event outcomes.
Low-density lipoproteins (LDLs) are the most abundant circulating lipoproteins and the most critical factor in the development of atherosclerosis. This protocol allows the staining of LDLs with oil red O to monitor particle uptake in bright-field microscopy. Here, we describe how to stain isolated LDLs using oil red O and how to use them to monitor LDL uptake in time-lapse experiments or fixed cells.
View Article and Find Full Text PDFPurpose Of Review: This review aims to summarize the most recently published literature highlighting the potential of pharmacological inhibition of ANGPTL3 in treating patients suffering from dyslipidemias. The rational for this strategy will be discussed considering evidence describing the role of ANGPTL3 in lipid metabolism and the consequences of its deficiency in humans.
Recent Findings: Recent trials have demonstrated the efficacy and safety of ANGPTL3 inhibition in treating homozygous familial hypercholesterolemia even in those patients carrying biallelic null/null variants, thus supporting the notion that the LDL-lowering effect of ANGPLT3 inhibition is LDLR-independent.